Tracking dynamic evolution of low‐ and intermediate‐risk differentiated thyroid cancer: Identification of individuals at risk of recurrence
Authors' conclusion
Patients with DTC classified as low- or intermediate-risk of recurrence with excellent response to treatment at FU1 rarely develop structural disease and this occurs almost exclusively in the first 5 years. Initial DRS status is an accurate tool for determining the risk of recurrence.
Study context
- Population
- Low- or intermediate-risk differentiated thyroid cancer (DTC) patients; mean follow-up 8.2 ± 6.2 years
- Participants
- 299 participants
- Exposure
- Response to treatment at FU1 by American Thyroid Association (ATA) dynamic risk stratification (DRS) category
- Excellentn = 181
- Indeterminaten = 81
- Biochemical incompleten = 26
- Outcome
- Structural recurrence
Methodological detailsATA dynamic risk stratification
- ATA dynamic risk stratification
Main finding
As reported in the abstract
Structural recurrence by DRS at FU1 · mean follow-up 8.2 ± 6.2 years
Observational data: associations, not effects.
Further findings
Risk factors of recurrence: excellent, indeterminate and biochemical incomplete vs structural incomplete response at end of follow-up
- Univariate: tumour size
- P < 0.001
- Univariate: T status
- <0.001
- Univariate: positive lymph nodes (N)
- P < 0.01
- Univariate: multifocality
- P < 0.004
- Univariate: need of additional radioactive iodine (RAI)
- P < 0.0001
- Univariate: first DRS status
- P < 0.0003
- Multivariate: only RAI remained significant
- P < 0.02
Risk factors of recurrence: excellent and indeterminate vs biochemical and structural incomplete responses
- Tumour size
- P < 0.0004
- T
- P < 0.01
- N
- P < 0.0001
- Bilaterality
- P < 0.03
- First DRS status
- P < 0.0001
- RAI
- P < 0.001
- Multivariate: T confirmed
- P < 0.01
- Multivariate: first DRS confirmed
- P < 0.0006
Original publication
Tracking dynamic evolution of low‐ and intermediate‐risk differentiated thyroid cancer: Identification of individuals at risk of recurrence. Clin Endocrinol (Oxf). Published 22 July 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →